All In Biotech

Drug Trial Radar · NCT07734870

Tirzepatide for Treatment of CCCA

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

May 25, 2028

Study completion May 25, 2028

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Eli Lilly and Company
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: * Does tirzepatide improve the symptoms and signs of active CCCA? * Does tirzepatide change the activity of genes in the scalp, especially genes related to scarring? * Does tirzepatide promote hair regrowth? Participants will: * Inject tirzepatide once a week for 12 months. * Visit the clinic for scalp examinations, photographs, and other health assessments. * Have scalp biopsies at the beginning of the study and after 6 months of treatment. * Have blood tests and other safety monitoring during the study. There is no separate comparison group. Researchers will compare each participant's results during treatment with the participant's results at the beginning of the study.

Conditions

  • Central Centrifugal Cicatricial Alopecia (CCCA)

Interventions

  • TirzepatideDrug

    Tirzepatide solution will be self-administered by subcutaneous injection once weekly. Participants will receive 2.5 mg once weekly for the first 4 weeks, followed by 5 mg once weekly for the remainder of the 12-month treatment period. Injection sites will be rotated among the abdomen, thigh, or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool ScoreTime frame: Baseline, 3 months, 6 months
  2. Change in Scalp Gene-Expression ProfilesTime frame: Baseline, 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Outpatient Center

    Baltimore, Maryland · Recruiting

  • Medical Pavilion at Howard County

    Columbia, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.